578729-05-2

Basic information

• Product Name: Carbamic acid, [(1R)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-, 1,1-dimethylethyl ester
• Synonyms: {(R)-1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-ethyl}-carbamic acid tert-butyl ester;(R)-tert-butyl 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethylcarbamate;tert-butyl (1R)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethylcarbamate
• CAS NO: 578729-05-2
• Molecular Formula: C19H30BNO4
• Molecular Weight: 347.262
• Mol File: 578729-05-2.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [(1R)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1R)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-, 1,1-dimethylethyl ester(578729-05-2)
• EPA Substance Registry System: Carbamic acid, [(1R)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-, 1,1-dimethylethyl ester(578729-05-2)

Safety Data

• Hazardous Substances Data: 578729-05-2(Hazardous Substances Data)

Usage

General Description

Carbamic acid, [(1R)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-, 1,1-dimethylethyl ester is a chemical compound with potential applications in the pharmaceutical and agrochemical industries. It is an ester derivative of carbamic acid, containing a boron-containing phenyl moiety. Carbamic acid, [(1R)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-, 1,1-dimethylethyl ester has been studied for its potential as a novel drug candidate and as a building block for the synthesis of other bioactive compounds. Its unique structure and properties make it an interesting target for further research and development in the field of medicinal chemistry and chemical synthesis.

Upstream product

• 27298-99-3 (R)-1-(4-chlorophenyl)ethylamine 
• 73183-34-3 bis(pinacol)diborane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 24358-62-1 (R)-1-(4-bromophenyl)ethylamine 
• 578729-21-2 [(R)-1-(4-bromo-phenyl)-ethyl]-carbamic acid tert-butyl ester 

Downstream Products

• 1338545-57-5 (R)-tert-butyl 1-(4-(8-methoxy-6-methyl-4-oxo-4,5-dihydrothieno[2,3-c]quinolin-9-yl)phenyl)ethylcarbamate 
• 871720-08-0 (R)-(4-(1-((tert-butoxycarbonyl)amino)ethyl)phenyl)boronic acid 
• 1431551-93-7 tert-butyl ((R)-1-(4'-((4S,5R)-3-(2,2-dichloroacetyl)-4-(fluoromethyl)-2,2-dimethyloxazolidin-5-yl)-[1,1'-biphenyl]-4-yl)ethyl)carbamate 
• 1346819-06-4 (R)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanamine hydrochloride 
• 1338544-26-5 (R)-tert-butyl methyl(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)carbamate 

Relevant articles and documents

Potential Foldamers Based on an ortho-Terphenyl Amino Acid

We describe the synthesis and characterization of a new class of oligomers built from a terphenyl-based amino acid. These oligomeric amides are of interest because the adoption of specific conformations could potentially be driven by the coordinated formation of inter-residue hydrogen bonds and aromatic interactions. Although high-resolution structural data have proven inaccessible, circular dichroism and nuclear magnetic resonance studies suggest that the new oligomers fold concomitantly with discrete self-association in chloroform.

Design, synthesis and biological evaluation of novel 1-phenyl phenanthridin-6(5H)-one derivatives as anti-tumor agents targeting TOPK

T–lymphokine-activated killer cell–originated protein kinase (TOPK) is a serine-threonine mitogen-activated protein kinase that is highly expressed in many types of human cancer. Due to its important role in cancer progression, TOPK is becoming an attractive target in chemotherapeutic drug design. In this study, a series of 1-phenyl phenanthridin-6(5H)-one derivatives have been identified as a novel chemical class of TOPK inhibitors. Some of them displayed very potent anti-cancer activity with IC50s less than 100 nM, superior than reference compound OTS964. The most potent compound, 9g suppressed the growth of cancer cells by apoptosis and specifically inhibited the activities of TOPK. Oral administration of 9g effectively suppressed tumor growth with TGI >79.7% in colorectal cancer xenograft models, demonstrating superior efficacy compared to OTS964. Pharmacokinetic studies reveal its good oral bioavailability. Our findings therefore show that 9g is a specific inhibitor of TOPK both in vitro and in vivo that may be further developed as a potential therapeutic agent against colorectal cancer.

PHARMACEUTICALLY ACTIVE COMPOUNDS

The invention is directed to compounds of general formula (I), and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.